SGMT Sagimet Biosciences Inc.
Sagimet Biosciences Inc. (SGMT) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +10.2% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel therapeutics targeting dysfunctional metabolic pathways. Sagimet Biosciences Inc. is based in SAN MATEO, Calif.
Sector
Healthcare
Industry
Biotechnology